Findings

What do systematic reviews say?

119 questions · 124 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 8.1%GRADE not reported 4 · 3.2%Very low 27 · 21.8%Low 32 · 25.8%Moderate 27 · 21.8%High 24 · 19.4%

Pregabalin 300 mg or 600 mg vs placebo

mg pregabalin · adults with moderate or severe neuropathic pain

2 findings from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
300 participants
GRADE not reported
Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
600 participants
GRADE not reported

Pregabalin vs cetirizine with pheniramine maleate (antihistamine)

Change in burn‐related pruritus (VAS) ( · people with postburn pruritus

Pregabalin showed no clear difference in change in burn‐related pruritus (VAS) ( compared with cetirizine with pheniramine maleate (antihistamine) (low certainty).

1 finding from 1 review

Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Pregabalin vs cetirizine with pheniramine maleate (antihistamine)

Adverse effects: drowsiness (gabapentin alone) · people with postburn pruritus

Pregabalin may leads to lower adverse events (drowsiness) compared with cetirizine with pheniramine maleate (antihistamine) (low certainty).

1 finding from 1 review

Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
RR 0.04 [0, 0.69]
1 study · 40 participants
Low

Pregabalin vs cetirizine with pheniramine maleate (antihistamine)

Pain · people with postburn pruritus

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use

It is very uncertain whether pregabalin changes benzodiazepine discontinuation, end of intervention compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
RR 1.44 [0.92, 2.25]
1 study · 106 participants
Very low

Pregabalin vs placebo

Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Pregabalin vs placebo

Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Very low

Pregabalin vs placebo

Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Pregabalin vs placebo

Adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo at end of treatment

At least 50% reduction in pain · patients with fibromyalgia

Pregabalin leads to higher 50% pain reduction compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.59 [1.33, 1.9]
5 studies · 3256 participants
High

Pregabalin vs placebo at end of treatment

Patient Global Impression of Change much or very much improved · patients with fibromyalgia

Pregabalin leads to higher patient Global Impression of Change of 'much' or 'very much' improved compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.38 [1.23, 1.55]
5 studies · 3183 participants
High

Pregabalin vs placebo at end of treatment

Fatigue · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3195 participants
High

Pregabalin vs placebo at end of treatment

Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3139 participants
High

Pregabalin vs placebo at end of treatment

Withdrawals due to adverse events · patients with fibromyalgia

Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.68 [1.36, 2.07]
5 studies · 3259 participants
High

Pregabalin vs placebo at end of treatment

Serious adverse events · patients with fibromyalgia

Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.03 [0.71, 1.49]
4 studies · 2729 participants
Moderate